Opinions are divided regarding the best prophylactic regimen for GVHD. The aim of this study was to evaluate potential survival benefit of different prophylactic regimens for acute GVHD (aGVHD). We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) including patients undergoing Allo-SCT. We included trials that assessed the addition of MTX, compared CsA and tacrolimus and evaluated the addition of steroids. Outcomes assessed were all-cause mortality (ACM) at the longest follow-up, aGVHD, chronic GVHD, TRM, relapse rate and regimen-specific adverse events. Relative risks (RRs) with 95% confidence intervals (CIs) were estimated and pooled. The regimen of MTX-CsA vs CsA alone (four trials) yielded no statistically significant difference in ACM (RR ¼ 0.84 (0.61-1.14)), but a significant decrease in aGVHD (RR ¼ 0.52 (0.39-0.7)). There was no difference in ACM for the comparison of MTX-CsA and MTXtacrolimus (three trials); however, MTX-tacrolimus was superior to MTX-CsA in the reduction of aGVHD (RR ¼ 0.62 (0.52-0.75)) and severe aGVHD ). The addition of steroids did not affect the outcomes (four trials). We conclude that MTX-CsA and MTX-tacrolimus are both acceptable alternatives for GVHD prophylaxis, although MTX-tacrolimus may be superior in terms of aGVHD reduction.
Introduction
GVHD is one of the major causes of death in patients undergoing allogeneic hematopoietic SCT (Allo-HSCT). Despite prophylactic measures, the incidence of acute GVHD (aGVHD) is estimated to be 40-60% among patients receiving transplants from HLA-identical sibling donors and reaches 75% in patients receiving HLAmatched unrelated (MUD) transplants. 1 The incidence of chronic GVHD (cGVHD) ranges between 40 and 70% and is one of the leading causes of death in Allo-HSCT survivors, estimated to cause 20-25% of late deaths. 2, 3 Other major causes are relapse and infection, which are estimated to cause around 30% and 10% of deaths, respectively. 3 The tight association between the degree of GVHD and TRM caused vigorous attempts to find strategies to decrease its severity. 4 Several approaches have been practiced and are currently used as part of transplantation protocols. Presently, GVHD prophylaxis is based on a calcineurin inhibitor, such as CsA or tacrolimus and a short course of MTX. Other pharmacologic options include corticosteroids, mycophenolate mofetil and sirolimus in various combinations. [5] [6] [7] [8] A regimen based on MTX with a calcineurin inhibitor is considered common practice and is recommended by the EBMT WP-PD (European group for BMT-working party pediatric diseases), IBFM-SG (the international BerlinFrankfurt-Munster (BFM) study group)-a subcommittee for BMT and by the ECOG (eastern cooperative oncology group).
We undertook this systematic review of randomized controlled trials (RCTs) to assemble all evidence available regarding the currently recommended regimens to elucidate whether there is a superior prophylaxis regimen, mainly in terms of all-cause mortality (ACM).
Materials and methods

Data sources
We conducted a comprehensive search strategy to identify both published and unpublished trials, with no restriction on language or study years. Relevant trials were identified by searching The Cochrane Library (Issue 2, 2008), PubMed (January 1966 and onwards), LILACS and CANCERLIT. We searched the following conference proceedings (from 2002): the American Society of Hematology, the American Society of Clinical Oncology and the European Hematology Association. We also searched the IBMTR (international BMT registry), EBMT and conferences of Experimental Hematology (http://www.iseh.org/ i4a/pages/index.cfm) for relevant abstracts. The following trial databases were searched for ongoing and unpublished trials: Current Controlled Trials in the metaRegister of controlled clinical trials (http://www.controlled-trials.com/) and the National Institutes of Health Clinical Trials Registry (http://clinicaltrials.gov/). The references of all identified studies were inspected for more trials. Additionally, the first or corresponding author of each included trial was contacted for information regarding unpublished trials or complementary information on their own trial.
Study selection
We included only RCTs. We also included trials assessing patients with hematological diseases (both malignant and nonmalignant) undergoing allogeneic BMT and SCT. We chose to include the following comparisons of regimens that are currently considered common practice for GVHD prophylaxis:
9 MTX-containing regimens vs the same regimens without MTX, MTX-tacrolimus regimen vs MTXCsA regimen and steroid-containing regimens vs the same regimens without steroids. We included trials that reported the outcomes up to 5 years following transplantation. We chose a follow-up of 5 years because this time span encompasses deaths from different causes (aGVHD, cGVHD, other causes of TRM and relapse-related mortality).
We used the following search term for all electronic databases: 'graft versus host disease' or 'graft versus host' or 'GVHD.' For PubMed, we added the Cochrane highly sensitive search term for identification of clinical trials. 10 Two reviewers independently inspected each reference identified by the search and applied inclusion criteria. For possibly relevant articles, or in cases of disagreement between the two reviewers, the full article was obtained and inspected independently by the two reviewers.
Data extraction and quality assessment Two reviewers independently extracted data from the included trials (RR and AG). In the event of any disagreement between the two reviewers, a third reviewer extracted the data (MP). Data extraction was discussed, decisions were documented and, where necessary, the authors of the trials were contacted for clarification and complementary information on their trials.
Two reviewers independently assessed trials for methodological quality (RR and AG). We individually assessed the following methodological quality measures: allocation concealment, generation of the allocation sequence and blinding. We graded allocation concealment and generation as adequate, unclear or inadequate. 10 
Outcomes
The primary outcome measure was ACM at the end of the study period. When long-term follow-up was reported, mortality data at the longest available time point were used for analysis. Secondary outcomes included the number of patients with grade II-IV aGVHD and severe aGVHD (grade III-IV) at 100 days, the number of patients with cGVHD at the end of study, TRM, number of patients who relapsed during the study period and number of patients with infections (bacterial, fungal and cytomegalovirus). Adverse events including renal failure and veno-occlusive disease were also assessed.
Data synthesis and analysis Dichotomous data were analyzed by calculating the relative risk (RR) for each trial with 95% confidence intervals (CIs; review manager version 4.2). For the main outcome, ACM, we performed an intention-to-treat analysis in which we included all known events in both nominator and denominator, even if excluded from the trial's original analysis. We assessed heterogeneity of trial results by calculating a w 2 -test of heterogeneity and the I 2 measure of inconsistency. The Mantel-Haenszel fixed effect model was used for pooling trial results and is shown unless statistically significant heterogeneity was found (P ¼ o0.10 or I 2 ¼ 450%), in which case a random effects model is presented. Correlations were assessed using the Pearson's correlation coefficient with a two-tailed test of significance (SPSS v.14).
Results
The search yielded 747 potentially relevant trials of which 36 were considered for further investigation. Of these, 20 studies were excluded for various reasons (Figure 1 ). 7, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Thirteen trials conducted between the years 1985 and 2007, and randomizing 1439 patients, fulfilled the inclusion criteria. Six trials assessed the addition of MTX to a calcineurin inhibitor (five trials assessed MTX-CsA vs CsA and one trial assessed MTX-tacrolimus vs tacrolimus). 6, [30] [31] [32] [33] [34] Five trials assessed the addition of corticosteroids to various regimens. 5, 6, [35] [36] [37] Three trials compared tacrolimus and CsA. [38] [39] [40] We also included three publications of longterm follow-up for the above trials. [41] [42] [43] All trials included patients undergoing transplantation from a matched related donor (MRD) or matched unrelated donor (MUD) following the myeloablative conditioning. All patients had a malignant hematological disease. The mean duration of follow-up among all studies was 45 months (range: 24-96). Data regarding demographics, host and donor characteristics, transplantation protocol and post-transplantation data are summarized in Table 1 . Seven trials were of adequate methodological quality, in terms of allocation generation and allocation concealment, and none were blinded (Table 1) . Among all trials, regardless of the regimen assessed, the risk for mortality at the end of the study was significantly correlated with the risks for severe aGVHD and aGVHD (R ¼ 0.65, P ¼ 0.001, 12 study arms and R ¼ 0.60, P ¼ p0.001, 14 study arms).
Data regarding infections were scarce and were analyzed only for the comparison of the addition of steroids to other regimens.
The addition of MTX to calcineurin inhibitors ACM. Overall, there was no statistically significant difference in ACM at the end of the study period There was no difference in severe aGVHD between the two arms, (RR ¼ 0.74 (95% CI ¼ 0.08-7.09), I
2 ¼ 77%, random effects model). However, this was derived from only two trials reporting opposite results.
There were no statistically significance differences in cGVHD (RR ¼ 0.84 (95% CI ¼ 0.7-1.02), five trials); TRM
2 ¼ 73%, random effects model, three trials).
Tacrolimus-containing regimens vs CsA-containing regimens ACM. There was no difference in ACM between tacrolimus-containing regimens and CsA-containing regimens (RR ¼ 1.10 (95% CI ¼ 0.93-1.3), three trials, Figure 3 ). In one study with unclear randomization methods, study arms were unbalanced with respect to age, baseline disease, and pre-transplant disease status. 40 After excluding this study from the analysis, there was still no difference in ACM between the two arms (RR ¼ 0.95 (95% CI ¼ 0.74-1.23), two trials).
For this outcome, we conducted a subgroup analysis according to donor type. Data were too scarce to analyze in the MRD group. There was no difference in (6) MRD (30) MUD (32) Other (3) Nash et al. Figure 3) . Similarly, there was a significant reduction in severe aGVHD with MTX-tacrolimus compared with MTX-CsA (RR ¼ 0.67 (95% CI ¼ 0.47-0.95), three trials). Sensitivity analysis excluding the above-described study 40 did not affect results. Subgroup analysis revealed the same significant reduction in aGVHD with MTX-tacrolimus for the MUD patient subgroup (RR ¼ 0.65 (95% CI ¼ 0.51-0.82), two trials).
There was no change in the incidence of cGVHD (RR ¼ 1.05 (95% CI ¼ 0.87-1.25), three trials; Figure 3) , TRM (RR ¼ 1.00 (95% CI ¼ 0.64-1.57), I
2 ¼ 69.7%, random effects model) and relapse rate (RR ¼ 1.26 (95% CI ¼ 0.92-1.71)). Sensitivity analysis did not affect results. As for adverse events, there was a significantly higher incidence of acute renal failure with MTX-tacrolimus (RR ¼ 1.20 (95% CI ¼ 1.03À1.39)), Figure 3 .
The addition of corticosteroids to other regimens ACM. There was no difference in ACM at the end of the study period between patients receiving or not receiving corticosteroids for GVHD prophylaxis (RR ¼ 0.95 (95% CI ¼ 0.8-1.14), four trials).
Secondary outcomes. There was no difference in aGVHD or severe aGVHD in the steroid-containing arm as compared with no steroids (RR ¼ 0.83 (95% CI ¼ 0.57-1.21), I
2 ¼ 52%, random effects model, five trials) and (RR ¼ 0.87 (95% CI ¼ 0.61-1.24), four trials), respectively.
There was no difference in the risk for cGVHD between the two arms (RR ¼ 1.15 (95% CI ¼ 0.72-1.83), random effects model, I
2 ¼ 70%, four trials). There was no change in the risk for bacterial and fungal documented infections (RR ¼ 0.85 (95% CI ¼ 0.55-1.32) and RR ¼ 1.20 (95% CI ¼ 0.56-2.6), three trials, respectively).
There was no difference in relapse rate or in the TRM between the two arms (RR ¼ 0.86 (95% CI ¼ 0.612-1.19), four trials) and (RR ¼ 1.01 (95% CI ¼ 0.71-1.42), three trials), respectively.
Discussion
Our systematic review of prophylaxis regimens for patients undergoing Allo-HSCT yielded two main clinically significant results. The first is no superiority of the different prophylaxis regimens in terms of ACM. The second is the superiority of CsA-MTX over CsA and the advantage of MTX-tacrolimus over MTX-CsA in terms of aGVHD reduction.
Our first comparison of calcineurin inhibitor MTX vs calcineurin inhibitor showed no significant difference in (9) Heterogeneity: Chi 2 = 5.26, df = 5 (P = 0.39); I 2 = 5% Test for overall effect: Z = 5.13 (P < 0.00001) terms of ACM. However, there was a significant reduction of aGVHD with MTX, with an NNT of 4 (95% CI ¼ 3-7). There were no significant differences between the two arms in the other outcomes that we examined.
Our second comparison of tacrolimus vs CsA (both added to MTX) showed no difference in ACM between the two arms. Nevertheless, there was a significant reduction of aGVHD and severe aGVHD in the MTX-tacrolimus arm.
There were no significant differences in the other outcomes, although patients treated with MTX-tacrolimus had an increased risk for developing acute renal failure. It is noteworthy that one of the studies included in the metaanalysis was unbalanced with respect to baseline risk factors for mortality. 40, 44 When we eliminated this study for sensitivity analysis, results were not affected. Similar to our results, the superiority of tacrolimus-based regimens in MUD transplant has also been observed in a large retrospective study, 45 in which tacrolimus was found to decrease GVHD, but contrary to our study, to improve the overall survival. This superiority was not shown in MRD transplants. 45 In the available RCTs, tacrolimus was superior in terms of GVHD reduction in MUD, with no significant impact on overall survival. Both tacrolimus and CsA are calcineurin inhibitors. They are biologically different as tacrolimus is associated with more pronounced inhibition of the production of IL-2 by T-lymphocytes, a major mediator in the pathogenesis of GVHD. 1, 46 This might be an explanation for its advantage over CsA in the reduction of GVHD. Although limited by their sample size, RCTs constitute a better platform to assess the overall survival, adjusting for risk factors that cannot be foreseen or adjusted for in observational studies.
Our third comparison of the addition of corticosteroids did not show a benefit for additional corticosteroids.
Several meta-analyses examined survival and reduction of GVHD in patients undergoing Allo-HSCT. The addition of immunoglobulins 47 and hematopoietic growth factors 48 failed to show superiority in terms of ACM and GVHD. Different myeloablative conditioning regimens conferred similar results regarding ACM and incidence of GVHD.
49
There was also no change in ACM when allogeneic PBSC transplantation was compared with allogeneic BMT. 50 However, PBSCTs (PBSC transplants) were found to have a survival benefit over BMTs when four instead of three doses of MTX were used for GVHD prophylaxis. 51 All-cause mortality in patients undergoing Allo-HSCT results from several causes, mainly GVHD, relapse and infections. 3, 52 There is a complex relationship between these factors. A limited stage of aGVHD is associated with improved survival, 53 whereas severe aGVHD reduces survival among patients transplanted for malignant hematological diseases. cGVHD is associated with a decreased relapse rate, presumably by its GVL effect. Relapse by itself is a major contributor for reduced survival. Thus, GVHD and relapse are opposing outcomes. Using the data available from all RCTs, we showed that aGVHD, mainly severe aGVHD, was significantly correlated with ACM at the end of study period. However, despite the reduction in aGVHD by using prophylaxis, this did not translate into a significant reduction in ACM for all comparisons. This may be explained in several ways: first, GVHD prophylaxis has never been shown to reduce mortality in patients who received prophylaxis compared with patients who did not receive it, although this was evaluated only in three small nonrandomized studies. [54] [55] [56] Second, supportive and early directed treatments for established GVHD are beneficial. In fact, TRM in patients who respond to first-line therapy for aGVHD is reduced compared with patients who do not respond. 9, 57 The major limitation of this systematic review is the paucity of RCTs on GVHD prophylaxis. All our results claiming no difference are based on comparisons of few small studies; neither the primary studies nor the metaanalysis are powered to refute an existing difference. Our results should be read in light of this limitation. Furthermore, we could not address the role of newer drugs and strategies, such as sirolimus and mycophenolate mofetil as well as different strategies for T-cell depletion, such as antithymocyte globulin, as part of the prophylaxis regimens for GVHD. Some of our analyses were heterogeneous. This may be explained by different populations of patients. However, pooling of results is legitimate because when the analysis did yield a statistically significant result, all studies showed a variable degree of benefit for the intervention rather than divergent results. We could not conduct subgroup analysis according to donor status (MRD or MUD transplants) for the primary outcome of ACM because of sparse data in many of the trials. This subgroup analysis is especially important for evaluating the influence of the various regimens on relapse rate and ACM in the MRD group of patients, who are prone to relapse and may not benefit from enhanced GVHD prophylaxis. Furthermore, our conclusions may not be applicable to transplant following nonmyeloablative conditioning, as timing and presentation of GVHD occurrence are different.
Implications for practice and for research. Our review showed no survival benefit for the various regimens.
In terms of aGVHD reduction, the regimen of MTXCsA is superior to CsA alone and is a good option for GVHD prophylaxis in Allo-HSCT. MTX-tacrolimus may be superior to MTX-CsA in aGVHD reduction. There is probably no role for the addition of corticosteroids to any of the regimens. Well-controlled randomized trials that will further assess the feasibility of MTX-tacrolimus in different settings of hematological transplants are needed.
Clinicians can use our findings to tailor therapy for individual patients, depending on the desired balance between GVHD and graft vs tumor effect.
Newer pharmacological and biological methods should be pursued to decrease GVHD while maintaining the graft vs tumor effect.
All-cause mortality should be assessed as the primary end point in these future trials, because of the divergent effects of prophylaxis on GVHD and relapse rate of the primary disease.
